
New treatment could reverse disease that affects women over 65
It’s time to embark on a new treatment for a debilitating and incurable disease that affects millions of people.
It’s no secret that the body begins to break down in many ways as we age, from brain decline to loss of muscle mass and bone density.
And a new treatment could reverse the so-called “silent disease” that affects a quarter of women over 65.

A slow-developing disease that weakens and weakens bones, osteoporosis is often considered an inevitable part of aging.
While bone mass peaks in the late 20s and declines with age, a human clinical trial in Spain has found a way to reverse the damage with a cutting-edge treatment based on stem cell technology.
The trial, published in Cell, followed 10 patients with advanced osteoporosis who received a single infusion of their own mesenchymal stem/stromal cells (MSCs), the cells that create and repair bone.
The women saw a sustained 94% decrease in fragility fractures over the next two years, while fractures decreased from an average of eight per year before the infusions to 0.5 per year afterward.
The infusions also increased bone tissue by 70% after just four months, indicating the possibility that the treatment could not only prevent fractures from osteoporosis, but perhaps also reverse bone density loss.
Participants also reported a 34% reduction in bone pain and a 30% reduction in disability two years after treatment.
MSCs are collected from the marrow, the spongy tissue located in the center of bones, then multiplied in the laboratory.

While previous studies in mice showed that MSCs rarely ended up where they needed to be, the Spain-based research team found that the cells spread to the pancreas, where they could reverse the disease.
The team also wrote that the reduction in fractures was not due to lifestyle changes or medications, “since no fractures occurred during the post-infusion period in these patients.”
However, it is unclear whether MSCs returned directly to bone, despite significant changes in bone tissue area and bone mineral density.
And even with convincing results, using MSCs as a viable treatment for osteoporosis won’t be possible for years, due to their size and where they travel once in the body.
“MSCs are 20 to 30 micrometers in diameter, larger than a pulmonary capillary, so when they first pass through the circulation, 50 to 80 percent of them lodge in the lungs,” wrote physician Jan Schaefer, who was not involved in the study, on LinkedIn.
“Of the others, very few manage to penetrate the bone marrow on their own,” Schaefer explained. “You can circulate a potentially useful cell and get almost no results because it never reaches the tissue you want to treat.”
There was also no control group of women who did not receive infusions, and many participants were taking osteoporosis medications.
The research team behind the study seeks to answer these questions through a follow-up trial in a larger cohort of patients with advanced osteoporosis.
These participants will receive one of three treatments: modified MSCs derived from their own bone marrow, modified MSCs from a healthy donor, or no MSC treatment at all.
Gn Health